These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9273360)

  • 1. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction.
    Link G; Tirosh R; Pinson A; Hershko C
    J Lab Clin Med; 1996 Mar; 127(3):272-8. PubMed ID: 9273360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture.
    Hershko C; Link G; Tzahor M; Kaltwasser JP; Athias P; Grynberg A; Pinson A
    J Lab Clin Med; 1993 Sep; 122(3):245-51. PubMed ID: 8409700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
    Link G; Pinson A; Hershko C
    Blood; 1994 May; 83(9):2692-7. PubMed ID: 8167347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells.
    Link G; Konijn AM; Hershko C
    J Lab Clin Med; 1999 Feb; 133(2):179-88. PubMed ID: 9989770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
    Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
    Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of anthracycline cardiotoxicity by iron chelation.
    Hershko C; Pinson A; Link G
    Acta Haematol; 1996; 95(1):87-92. PubMed ID: 8604592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of iron and iron chelators in anthracycline cardiotoxicity.
    Hershko C; Link G; Tzahor M; Pinson A
    Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
    Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
    Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells.
    Link G; Saada A; Pinson A; Konijn AM; Hershko C
    J Lab Clin Med; 1998 May; 131(5):466-74. PubMed ID: 9605112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
    Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
    Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility.
    Link G; Pinson A; Hershko C
    J Lab Clin Med; 1993 Jan; 121(1):127-34. PubMed ID: 8426074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity.
    Elgharabawy RM; Elgharbawy DM; Emara AM
    Hum Exp Toxicol; 2018 Aug; 37(8):870-885. PubMed ID: 29172713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of deferiprone (L1) and deferoxamine on iron and essential element tissue level and parameters of oxidative status in dietary iron-loaded mice.
    Eybl V; Kotyzová D; Kolek M; Koutenský J; Nielsen P
    Toxicol Lett; 2002 Mar; 128(1-3):169-75. PubMed ID: 11869827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ
    Toxicol Lett; 1995 Oct; 80(1-3):1-18. PubMed ID: 7482575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin.
    Xu LJ; Jin L; Pan H; Zhang AZ; Wei G; Li PP; Lu WY
    Acta Pharmacol Sin; 2006 Oct; 27(10):1333-9. PubMed ID: 17007740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.